| Methods |
Retrospective cohort study |
| Participants |
56 confirmed cases |
| Interventions |
Ribavirin 2 g as an initial loading dose, then 1 g 4 x daily for 4 days, and then 0.5 g 4 x daily for 6 days
Oral ribavirin |
| Outcomes |
Mortality, length of hospitalisation, requirement for transfusion (FFP), requirement for transfusion (platelets), SAEs |
| Location and dates |
Ankara Training and Research Hospital in Central Anatolia, Ankara, Turkey tertiary centre 2007 ‐ 2010 |
| Number of days since onset of symptoms (mean/SD) |
Early ribavirin, median 2 (range = 1 ‐ 5 days); Late ribavirin, median 5 (range = 4 ‐ 8 days); No ribavirin, median 3 (range 1 ‐ 10 days) |
| Supportive therapy |
Erythrocytes, platelets, FFP, or hydration as needed |
| Notes |
Comparator ‐ late ribavirin |
